| HOME >> BIOLOGY >> TECHNOLOGY |
.
The company intends to hire during the remainder of 2008 12 additional salespersons and 3 wound-care certified nurses who specialize in in-service training, according to Bob Cole, Senior VP of Sales. "This broader coverage will help meet current and anticipated demand for the company's advanced wound-care products; if all goes well, the expansion could continue in 2009, especially as our R&D has been filling our product pipeline with additional cutting-edge products."
MEDIHONEY is the first honey-based product marketed in the US for advanced wound care, although similar products have been marketed in the UK and Europe for some time. It is comprised primarily of active Leptospermum honey, which is noted for its effects on wound healing and burn management. Derma Sciences also supplies products such as the antimicrobial silver-based ALGICELL(TM) Ag and a variety of additional proprietary wound-healing products.
About Derma Sciences
Derma Sciences is a manufacturer and marketer of advanced wound-care products, with operations based in the US and Canada, and sales worldwide. The company sources Active Manuka (Leptospermum scoparium) Honey from Comvita New Zealand, Ltd. Comvita controls over 70% of the flow of manuka honey, and owns several patents around the use of honey in wound dressings. The Company has also obtained FDA clearance to market and sell its MOBILITY-1(TM) boot and compressor device for the treatment of venous ulcers, lymphedema, and other conditions that require compression therapy. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.
Forward-looking Statements
Statements contained in this release that are not statements of
historical fact may be deemed to be forward-looking statements. Without
limiting the generality of the foregoing, words such as "may," "will,"
"expect," "believe," "antic
'/>"/>
| SOURCE Derma Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
3. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
6. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
7. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
10. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |